Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. more
Time Frame | ATOS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -14.4% | -3.72% | -0.05% |
1-Month Return | -16.41% | -1.85% | 2.75% |
3-Month Return | -29.14% | -11.4% | 7.4% |
6-Month Return | -6.96% | -4.41% | 10.47% |
1-Year Return | 48.59% | 4.13% | 27.57% |
3-Year Return | -43.68% | 0.3% | 29.56% |
5-Year Return | -23.02% | 36.62% | 89.3% |
10-Year Return | -99.37% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 52.79K | 46.60K | 23.00K | 8.00K | 23.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":88.28,"profit":true},{"date":"2021-12-31","value":43.57,"profit":true},{"date":"2022-12-31","value":15.15,"profit":true},{"date":"2023-12-31","value":43.57,"profit":true}] |
Gross Profit | (52.79K) | (46.60K) | (23.00K) | (8.00K) | (23.00K) | [{"date":"2019-12-31","value":-5278900,"profit":false},{"date":"2020-12-31","value":-4660000,"profit":false},{"date":"2021-12-31","value":-2300000,"profit":false},{"date":"2022-12-31","value":-800000,"profit":false},{"date":"2023-12-31","value":-2300000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 17.27M | 14.61M | 20.52M | 27.69M | 31.38M | [{"date":"2019-12-31","value":55.03,"profit":true},{"date":"2020-12-31","value":46.55,"profit":true},{"date":"2021-12-31","value":65.4,"profit":true},{"date":"2022-12-31","value":88.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (17.27M) | (14.61M) | (20.52M) | (27.69M) | (31.38M) | [{"date":"2019-12-31","value":-1726542500,"profit":false},{"date":"2020-12-31","value":-1460739200,"profit":false},{"date":"2021-12-31","value":-2052100000,"profit":false},{"date":"2022-12-31","value":-2769100000,"profit":false},{"date":"2023-12-31","value":-3137700000,"profit":false}] |
Total Non-Operating Income/Expense | 25.65K | (4.16M) | (79.00K) | 1.61M | 5.06M | [{"date":"2019-12-31","value":0.51,"profit":true},{"date":"2020-12-31","value":-82.21,"profit":false},{"date":"2021-12-31","value":-1.56,"profit":false},{"date":"2022-12-31","value":31.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (17.24M) | (17.83M) | (20.61M) | (26.96M) | (30.09M) | [{"date":"2019-12-31","value":-1723977700,"profit":false},{"date":"2020-12-31","value":-1782795200,"profit":false},{"date":"2021-12-31","value":-2060600000,"profit":false},{"date":"2022-12-31","value":-2696000000,"profit":false},{"date":"2023-12-31","value":-3009400000,"profit":false}] |
Income Taxes | (119.07K) | 3.27M | (213.56K) | (731.00K) | - | [{"date":"2019-12-31","value":-3.64,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-6.53,"profit":false},{"date":"2022-12-31","value":-22.35,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (17.12M) | (21.10M) | (20.39M) | (26.23M) | - | [{"date":"2019-12-31","value":-1712070600,"profit":false},{"date":"2020-12-31","value":-2109931300,"profit":false},{"date":"2021-12-31","value":-2039244200,"profit":false},{"date":"2022-12-31","value":-2622900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (17.24M) | (17.83M) | (20.61M) | (26.96M) | (29.83M) | [{"date":"2019-12-31","value":-1723977700,"profit":false},{"date":"2020-12-31","value":-1782795200,"profit":false},{"date":"2021-12-31","value":-2060600000,"profit":false},{"date":"2022-12-31","value":-2696000000,"profit":false},{"date":"2023-12-31","value":-2983100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.24M) | (21.10M) | (20.61M) | (26.23M) | (30.09M) | [{"date":"2019-12-31","value":-1723977700,"profit":false},{"date":"2020-12-31","value":-2109931300,"profit":false},{"date":"2021-12-31","value":-2060600000,"profit":false},{"date":"2022-12-31","value":-2622900000,"profit":false},{"date":"2023-12-31","value":-3009400000,"profit":false}] |
EPS (Diluted) | (2.04) | (1.97) | (0.18) | (0.21) | (0.27) | [{"date":"2019-12-31","value":-204,"profit":false},{"date":"2020-12-31","value":-197,"profit":false},{"date":"2021-12-31","value":-18,"profit":false},{"date":"2022-12-31","value":-21,"profit":false},{"date":"2023-12-31","value":-27,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ATOS | |
---|---|
Cash Ratio | 12.90 |
Current Ratio | 13.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ATOS | |
---|---|
ROA (LTM) | -20.35% |
ROE (LTM) | -31.30% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ATOS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ATOS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.91 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 2.01 |
PEG | NM |
Atossa Genetics Inc (ATOS) share price today is $1.07
Yes, Indians can buy shares of Atossa Genetics Inc (ATOS) on Vested. To buy Atossa Genetics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Atossa Genetics Inc (ATOS) via the Vested app. You can start investing in Atossa Genetics Inc (ATOS) with a minimum investment of $1.
You can invest in shares of Atossa Genetics Inc (ATOS) via Vested in three simple steps:
The 52-week high price of Atossa Genetics Inc (ATOS) is $2.31. The 52-week low price of Atossa Genetics Inc (ATOS) is $0.7.
The price-to-earnings (P/E) ratio of Atossa Genetics Inc (ATOS) is
The price-to-book (P/B) ratio of Atossa Genetics Inc (ATOS) is 1.91
The dividend yield of Atossa Genetics Inc (ATOS) is 0.00%
The market capitalization of Atossa Genetics Inc (ATOS) is $140.90M
The stock symbol (or ticker) of Atossa Genetics Inc is ATOS